Professor Min-shan Chen is currently the director of Liver Surgery Department. He has been leading an experienced multi-disciplinary team (MDT) for the diagnosis and treatment of liver cancers. The MDT provides individualized case management for patients, whose modalities include: laparoscopic hepatectomy, robotic-assisted laparoscopic hepatectomy, thermal ablation, transarterial intervention, etc. He has published more than 100 papers as the corresponding author or first author, and 6 of which were cited by NCCN guidelines for liver cancer. Professor Chen is also the principle investigator of several multi-center researches, and the recipient of more than 10 national grants. To recognize his substantial contribution to the research field, he was listed as one of the Highly Cited Researchers by Elsevier.

Multi-disciplinary treatment of hepatocellular carcinoma, including minimally invasive surgery, thermal ablation, and transarterial intervention modalities.

M.D. Sun Yat-Sen University of Medical Sciences, 1981-1987

Ph.D. Oncology, Sun Yat-Sen University of Medical Sciences, 1996-2000

Selected publications

1. Peng Z W#, Zhang Y J#, Chen M S*, Xu L, Liang H H, Lin X J, Guo R P, Zhang Y Q, Lau W Y. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial [J]. J Clin Oncol, 2013, 31(4): 426-432. (IF 28.245)

2. Xu L#, Peng Z W#, Chen M S*, Shi M, Zhang Y J, Guo R P, Lin X J, Lau W Y. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization [J]. J Hepatol, 2015, 63(1): 122-130. (IF=18.946)

3. Fang J H#, Xu L#, Shang L R#, Pan C Z, Ding J, Tang Y Q, Liu H, Liu C X, Zheng J L, Zhang Y J, Zhou Z G, Xu J, Zheng L, Chen M S*, Zhuang S M*. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma [J]. Hepatology, 2019, 70(3): 824-839. (IF=14.971)

4. Lian Y F#, Huang Y L#, Zhang Y J#, Chen D M, Wang J L, Wei H, Bi Y H, Jiang Z W, Li P, Chen M S*, Huang Y H*. CACYBP Enhances Cytoplasmic Retention of P27(Kip1) to Promote Hepatocellular Carcinoma Progression in the Absence of RNF41 Mediated Degradation [J]. Theranostics, 2019, 9(26): 8392-8408. (IF=8.063)

5. Chen M S#*, Li J Q, Zheng Y, Guo R P, Liang H H, Zhang Y Q, Lin X J, Lau W Y. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma [J]. Ann Surg, 2006, 243(3): 321-328. (IF 7.6).

6. Zhang Y J#, Liang H H, Chen M S*, Guo R P, Li J Q, Zheng Y, Zhang Y Q, Lau W Y. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial [J]. Radiology, 2007, 244(2): 599-607. (IF 7.608)

7. Peng Z W#, Lin X J, Zhang Y J, Liang H H, Guo R P, Shi M, Chen M S*. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study [J]. Radiology, 2012, 262(3): 1022-1033. (IF 7.608)

8. Peng Z W#, Zhang Y J, Liang H H, Lin X J, Guo R P, Chen M S*. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial [J]. Radiology, 2012, 262(2): 689-700. (IF 7.608)

9. Chen J#, Peng K#, Hu D, Shen J, Zhou Z, Xu L, Chen J, Pan Y, Wang J, Zhang Y*, Chen M*. Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation [J]. Cancers (Basel), 2018, 10(10) (IF=6.162)

10. Peng Z W#*, Liu F R#, Ye S, Xu L, Zhang Y J, Liang H H, Lin X J, Lau W Y, Chen M S*. Radiofrequency ablation versus open hepatic resection for elderly patients (> 65 years) with very early or early hepatocellular carcinoma [J]. Cancer, 2013, 119(21): 3812-3820. (IF: 6.102)

Updated June 2020 by International Office, Sun Yat-sen University Cancer Center